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Abstract
Background: Both anaemia and cardiovascular disease (CVD) are common in people with diabetes. While individually both
characteristics are known to raise mortality risk, their combined influence has yet to be quantified. In this pooling project,
we examined the combined impact of baseline haemoglobin levels and existing CVD on all-cause and CVD mortality in
people with diabetes. We draw comparison of these effects with those apparent in diabetes-free individuals.
Methods/Principal Findings: A combined analyses of 7 UK population-based cohorts resulted in 26,480 study members.
There were 946 participants with physician-diagnosed diabetes, 2227 with anaemia [haemoglobin,13 g/dl (men) or ,12
(women)], 2592 with existing CVD (stroke, ischaemic heart disease), and 21,396 with none of the conditions. Across diabetes
and anaemia subgroups, and using diabetes-free, non-anaemic participants as the referent group, the adjusted hazard
ratios (HR) were 1.46 (95% CI: 1.30–1.63) for anaemia, 1.67 (1.45–1.92) for diabetes, and 2.10 (1.55–2.85) for diabetes and
anaemia combined. Across combined diabetes, anaemia and CVD subgroups, and compared with non-anaemic, diabetes-
free and CVD-free participants, HR (95% CI) for all-cause mortality were 1.49 (1.32–1.69) anaemia, 1.60 (1.46–1.76) for existing
CVD, and 1.66 (1.39–1.97) for diabetes alone. Equivalents were 2.13 (1.48–3.07) for anaemia and diabetes, 2.68 (2.14–3.36) for
diabetes and existing CVD, and 3.25 (1.88–5.62) for the three combined. Patterns were similar for CVD mortality.
Conclusions/Significance: Individually, anaemia and CVD confer similar mortality risks in people with diabetes, and are
excessively fatal in combination. Screening for anaemia would identify vulnerable diabetic patients whose outcomes can
potentially be improved.
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Introduction
Anaemia is frequent in people with diabetes where it is generally
undetected and therefore untreated [1,2]. There is evidence that
anaemia is associated with microvascular complications of diabetes
[2,3,4]. In both diabetic and nondiabetic subjects, anaemia is a
determinant of all-cause and cardiovascular disease (CVD)
mortality [1,5,6]; although whether such association is consistent
across a broader population with diabetes is still equivocal [7,8,9].
CVD is common in people with diabetes [10] and CVD often
co-exists with anaemia. While individually, both CVD and
anaemia are known to raise mortality risk, their combined
influence has yet to be quantified, particularly in the general
population. Accordingly, in this pooling project, we examined the
combined association of baseline haemoglobin levels and existing
CVD with all-cause and CVD mortality in people with diabetes.
We draw comparison of these effects with those in people who are
diabetes-free.
Materials and Methods
Participants were 26,480 individuals with data available on
diabetes status (history of physician-diagnosed) and total haemo-
globin level at baseline [11]. Study members were drawn from 7
prospective UK studies comprising both Scottish Health Surveys
(1995 & 1998) and the Health Surveys for England (1994, 1998,
1999, 2000 & 2004) [11,12]. All cohorts were representative of the
general population, sampling individuals living in households in
each country. Participants gave full informed written consent and
ethical approval was obtained from the London Research Ethics
Council.
The full study protocol has been described in detail elsewhere
[13,14,15]. In brief, participants were visited twice in their homes.
During the first of these meetings, trained interviewers collected
data on demographics and health behaviours, including socioeco-
nomic status, self-reported smoking, alcohol and physical activity.
Interviewers made enquiries about existing physician-diagnosed
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CVD (stroke, ischemic heart disease, angina symptoms), other
medical conditions and treatments. During the second visit,
conducted within a few days of the first, nurses gathered clinical
data. This included total haemoglobin which was assayed from a
non-fasting peripheral blood sample.
Systolic and diastolic blood pressure was measured with an
Omron HEM-907 blood pressure monitor three times in the
sitting position after 5-min rest between each reading. The average
of the second and third BP recordings was used for the present
analyses. Height and weight were measured directly by the
interviewers using Chasmors stadiometers (Chasmors Ltd, Lon-
don, UK) and Tanita electronic digital scales (Tanita, Corpora-
tion, Tokyo, Japan), respectively. BMI was calculated using the
usual formulae (weight [kg]/height [m2]). Waist and hip
circumferences were measured using a tape with an insertion
buckle at one end. Waist circumference was measured at the
midpoint between the lower rib and the upper margin of the iliac
crest. Hip circumference was denoted by the widest circumference
around the buttocks, below the iliac crest. Both measurements
were taken twice, using the same tape, and were recorded to the
nearest even millimetre. Those whose two waist or hip measure-
ments differed by more than 3 cm had a third measurement taken.
The mean of the two valid measurements was used in our analysis.
Cholesterol was measured using cholesterol oxidase assays on an
Olympus 640 analyzer. Anaemia was defined as haemoglobin
concentrations ,13 g/dl (men) and ,12 g/dl (women), following
the World Health Organisation criteria [16].
Ascertainment of Disease-specific Mortality
Consenting participants were linked to UK National Health
Service records from which a death certificate was located.
Classification of the underlying cause of death was based on
information on the death certificate together with any additional
observations made by the certifying physician. Diagnoses for
primary cause of death used the ninth (ICD-9) and tenth (ICD-10)
revisions of the International Classification of Diseases. Cardio-
vascular disease codes were 390–459 for ICD-9 and I01–I99 for
ICD-10.
Statistical Methods
The starting study sample comprised 57,073 participants,
among whom 28,809 (46.2%) had provided blood sample for
total haemoglobin assays. Sixteen were excluded for missing data
on diabetes status. Other 2313 participants who did not consent
for mortality follow-up were also excluded. Therefore primary
analyses were based on 26,480 individuals (12,135 men) with data
available on age, sex, diabetes status and haemoglobin level at
baseline (Figure S1). Of these participants, 23,129 had complete
data on covariates and were included in multivariable model
analyses. In the Table S1 we present the baseline characteristics of
study members included and excluded from the analytical sample.
Differences were small in magnitude and clinically trivial but
attained statistical significance for many characteristics owing to
the large numbers. For instance, mean baseline variables
(participants in the primary analysis vs. those excluded) were
26.9 vs. 27.3 kg/m2 for body mass index, 90 vs. 91 cm for waist
circumference, 0.86 vs. 0.87 for waist/hip ratio and 5.9 vs.
5.8 mmol/l for total cholesterol (all p#0.002 for difference).
Participants were classified according anemia and prior CVD
status, then further grouped by baseline diabetes status. Baseline
comparisons used logistic regressions and generalized linear
regression models. A Poisson model was used to determine the
absolute risk of CVD and all-cause mortality during follow-up by
status for anaemia, and for prior CVD. Kaplan-Meier estimator
was used to compute the probability of death during follow-up and
estimates compared across baseline stratification variables with the
use of the Log-Rank test. Cox regression models were used to
investigate the associations of anaemia and prior CVD with
mortality after adjustment for cohort, age, sex, smoking, systolic
blood pressure, body mass index and total cholesterol.
To investigate the association between total haemoglobin and
mortality risks, Cox models were used to compute the hazard ratio
and accompanying 95% confidence interval (95% CI) for a one
standard deviation (SD) decrease in total haemoglobin in relation
to all-cause and CVD mortality. Similar Cox models were used to
compare mortality risk across fifths of haemoglobin, with 95% CI
derived with the used of floating absolute risk methods [17]. Fifths
of haemoglobin were sex specific to account for sex differences in
the distribution of haemoglobin. The ‘shape’ of the associations of
haemoglobin with mortality risks was investigated with the use
of restricted cubic spline and by fitting the polynomial terms of
haemoglobin. Different functional forms were compared through
likelihood ratio x2 and Akaike’s information criterion (AIC). [18]
Data analyses used SAS/STATH v 9.1 for windows (SAS Institute
Inc., Cary, NC, USA) and the statistical package R v.2.12.2
[(2011-02-25), The R Foundation for statistical computing,
Vienna, Austria].
Sensitivity Analyses
Among eligible participants, 13,228 (424 with diabetes, 3.3%)
had data available on CRP levels. Multivariable Cox regression
analyses were conducted in this subgroup with further adjustment
for CRP levels to investigate the potential effects of chronic
inflammation on the observed results.
Results
Baseline Profile
The study sample included 26,480 participants amongwhom 946
(3.6%) had diabetes. The prevalence of anaemia was higher (14.3%;
n= 135) in participants with diabetes than those without (8.2%;
n= 2092; p-value for difference ,0.001). Compared to their non-
anaemic counterparts, participantswith anaemiaweremore likely to
be female, to smoke, and havewith a history ofCVD.Theywere also
older but had lower systolic blood pressure, body mass index, waist
circumference and total cholesterol (Table 1). In addition, the
expected adverse profile of risk factors was observed in participants
with diabetes as compared to those without. The characteristics of
Participantscross-classifiedbyanaemiaandpriorCVDarepresented
inTableS2.Amongdiabeticandnondiabeticparticipants, thosewith
anaemia and existing CVD were older and less likely to be current
smokers (all p#0.008) Differences were also apparent in the
distribution of other baseline variables, however with no consistent
pattern (Table S2). The characteristics of participants according to
status for diabetes and across fifths of total haemoglobin distribution
are shown inTable S3. Age decreased with increasing haemoglobin,
while increasingtrendwasobservedforothervariables (allp#0.02for
linear trend).
Effects of Anaemia on Mortality Risk
During follow-up, 4643 deaths from all cause were recorded, of
which 1347 (29%) were from cardiovascular disease. The number
of fatal outcomes in participants with diabetes was 378 for all-
cause mortality and 133 for cardiovascular mortality.
The absolute risk (95% CI) per 1000 person-years for
participants with and without diabetes, and by status for anaemia
at baseline is shown in Table 2. In both people with and without
diabetes, anaemia was associated with increased incidence of all-
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cause and CVD mortality. Absolute risk of fatal events in
nondiabetic participants with anaemia was always lower than that
in diabetic participants without anaemia (Table 2).
The probability of survival during follow-up is depicted in
Figure 1. At any given time, the highest probability was always
recorded in nondiabetic non-anaemic participants and the lowest
in diabetic participants with anaemia. Across diabetes and
anaemia strata, survival probabilities among diabetes-free partic-
ipants with anaemia were similar to those among diabetic
participants without anaemia (Figure 1).
Using nondiabetics without anaemia as a reference group,
anaemia without diabetes was associated with 53% (24–88%)
higher risk of CVD mortality after adjustment for age, sex, prior
CVD, systolic blood pressure, current smoking, body mass index
and total cholesterol. Equivalents were 100% (57–153%) for
diabetes without anaemia and 96% (10–250%) for diabetes &
anaemia (Table 2).
Combined Effects of Anaemia and Existing CVD on
Morality Risk
The absolute risk of all-cause and CVD mortality (per 1000
person-years) by crossed status for anaemia and existing CVD is
summarised in Figure 2. For each grouping category by both
anaemia and existing CVD status, absolute risks were always
higher in diabetic than in non-diabetic participants. Absolute
risks were within the same range among diabetes-free partici-
pants with anaemia and existing CVD, non-anaemic diabetic
participants with existing CVD, and anaemic diabetic partici-
pants with no prior CVD. Having diabetes, anaemia and existing
CVD at least doubled the risk from having only any two
combinations of the three. These similarities and differences were
consistent through follow-up and after adjustment for several
baseline characteristics (Table S4). For instance, using nondia-
betic participants without anaemia and no existing CVD as a
reference, anaemia alone was associated with hazard ratio (95%
Table 1. Baseline characteristics by status for anaemia and diabetes.
Variables No diabetes Diabetes All participants
no anaemia Anaemia p-value no anaemia anaemia p-value
Anaemia (yes
vs. no)
Diabetes (yes
vs. no)
N 23442 2092 811 135
Women (%) 53.1% 70% ,0.001 44% 49.6% 0.22 ,0.001 ,0.001
Mean age, years (SD) 54.4 (13.2) 59.0 (17.1) ,0.001 61.9 (11.9) 68.8 (14.2) ,0.001 ,0.001 ,0.001
Current smoking (%) 27.4% 15.2% ,0.001 24.3% 11.9% 0.001 ,0.001 0.008
Mean systolic blood
pressure*, mmHg (SD)
137 (20) 134 (22) ,0.001 146 (21) 145 (25) 0.57 ,0.001 ,0.001
Mean resting heart rate,
bpm{ (SD)
71 (11) 71 (11) 0.13 74 (12) 74 (10) 0.65 0.06 ,0.001
Mean body mass index,
kg/m2 (SD)
27.0 (4.5) 25.8 (4.8) ,0.001 29.1 (5.1) 26.8 (4.1) ,0.001 ,0.001 ,0.001
Mean waist circumference,
cm (SD)
90.0 (12.9) 85.7 (12.4) ,0.001 98.6 (13.1) 94.1 (11) ,0.001 ,0.001 ,0.001
Mean waist/hip ratio (SD) 0.86 (0.09) 0.84 (0.08) ,0.001 0.92 (0.08) 0.91 (0.07) 0.10 ,0.001 ,0.001
Mean total cholesterol,
mmol/l (SD)
6.0 (1.2) 5.5 (1.1) ,0.001 5.8 (1.1) 5.3 (1.2) ,0.001 ,0.001 ,0.001
Median CRP, mg/l (25th–75th
percentiles)
1.8 (0.8–3.9) 1.6 (0.6–4.6) ,0.001 3.1 (1.5–6.4) 3.5 (1.0–16.6) 0.007 ,0.001 ,0.001
Existing cardiovascular
disease (%)
8.7% 14.3% ,0.001 26.6% 31.1% 0.28 ,0.001 ,0.000
SD, standard deviation.
doi:10.1371/journal.pone.0041875.t001
Table 2. Incidence all-cause and Cardiovascular and all-cause mortality per 1000 person-years of follow-up and hazard ratios.
Baseline classification CVD mortality All-cause mortality
Diabetes Anaemia
Event rate
(/1000 pys) HR (95% CI)* HR (95% CI){
Event rate
(/1000 pys) HR (95% CI)* HR (95% CI){
No No 4.2 (4.0–4.5) 1 1 14.8 (14.4–15.3) 1 1
No Yes 9.3 (8.7–11.7) 1.48 (1.20–1.81) 1.53 (1.24–1.88) 33.5 (31.0–36-2) 1.44 (1.29–1.60) 1.46 (1.30–1.63)
Yes No 15.2 (12. 6–18.3) 2.32 (1.84–2.94) 2.00 (1.57–2.53) 41.8 (37.3–46.9) 1.76 (1.53–2.02) 1.67 (1.45–1.92)
Yes Yes 29.0 (19.6–42.9) 2.08 (1.17–3.70) 1.96 (1.10–3.50) 90.5 (72.5–113.0) 2.22 (1.64–3.01) 2.10 (1.55–2.85)
*Cox models are adjusted for cohort, age, sex,
{Cox models are further adjusted for smoking systolic blood pressure, total cholesterol, BMI and prior CVD.
CI, confidence interval; HR, hazard ratio; prs, person-years.
doi:10.1371/journal.pone.0041875.t002
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CI) of 1.49 (1.32–1.69) for all-cause mortality, while diabetes was
associated with 1.66 (1.39–1.97). Equivalents were 2.13 (1.48–
3.07) for anaemia and diabetes; 2.68 (2.14–3.36) for diabetes and
existing CVD; and 2.14 (1.73–2.66) for anaemia and existing
CVD.
The Continuum of Total Haemoglobin and Mortality
In age, sex and cohort adjusted analysis, there was a weak
positive association between haemoglobin and all-cause mortality
[hazard ratio per SD lower haemoglobin: 1.07 (95% CI: 1.03–
1.10), with no significant heterogeneity by diabetes status (p = 0.08
for interaction). No continuous association was found for CVD
mortality. The shape of the associations for different coding of
total haemoglobin is depicted in Figure 3, and accompanying fits
statistics in Table S5. The linear form was always the least fitting
functional form, and curvilinear forms (U-shape) were always the
best fitting, with nadir of risk around 14 g/dl for haemoglobin
levels. Adjusted hazard ratios and confidence intervals for
mortality risk across quintiles of haemoglobin as depicted in
Figure S2. Using the top quintile as reference, significant higher
risk of mortality was observed only within the lowest quintile.
A total of 64 participants (5 with diabetes) had haemoglobin
levels within the range for defining polycythaemia (i.e. haemoglob-
in$18.5 g/dl in men or haemoglobin$16.5 g/dl). Among them
30 deaths (cumulative incidence 46.9%) were recorded, 5
(cumulative incidence 7.8%) being of cardiovascular origin. Using
participants with normal range haemoglobin levels as a reference
group, the age and sex adjusted hazard ratios (95% confidence
intervals) associated with all-cause mortality were 1.46 (1.34–1.59)
for anaemia and 2.70 (1.89–3.88) for polycythaemia. The
equivalents for CVD mortality were 1.28 (1.10–1.50) and 1.56
(0.65–3.77).
Sensitivity Analyses
Among participants with data available on CRP levels (13,228
participants), 1761 (136 in people with diabetes) deaths were
Figure 1. Kaplan-Meier estimates of the probability of all-cause and cardiovascular mortality during follow-up in participants with
and without diabetes, and by status for anaemia. The upper figure panel is for cardiovascular disease and the lower for all-cause mortality.
doi:10.1371/journal.pone.0041875.g001
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recorded during follow-up, of which 590 (61 in people with
diabetes) were from cardiovascular disease. Across diabetes and
anaemia strata, using nondiabetics without anaemia as a reference
group, the age and sex adjusted HR (95% CI) associated with
CVD mortality were 1.55 (1.17–2.04) for anaemia without
diabetes, 2.68 (2.01–3.58) for diabetes without anaemia and 2.23
(1.10–4.53) for both anaemia and diabetes. The equivalents after
further adjustment for prior CVD, systolic blood pressure, current
smoking, body mass index, total cholesterol and log(CRP) were
1.43 (1.08–1.90), 2.13 (1.58–2.86) and 1.81 (0.90–3.70). For all-
cause mortality, estimates were 1.39 (1.18–1.64), 1.83 (1.51–2.21)
and 2.20 (1.44–3.36) in sex age adjusted models, and 1.24 (1.05–
1.47), 1.65 (1.36–2.01) and 1.76 (1.15–2.71) after adjusted for all
covariates including CRP. The small number of participants in
some subgroups hampered our ability to reliably perform similar
analysis across diabetes, anaemia and prior CVD strata. Estimates
however were mostly similar to those from the main analysis
(Table S4).
Discussion
In this pooling of contemporary, community-based cohort
studies, we found that anaemia was associated with increased risks
of all-cause and cardiovascular disease mortality. The magnitude
of these risks in people with diabetes and no history of CVD were
similar to those conferred by a history of CVD. In diabetic
participants with existing CVD, anaemia conveyed very high
mortality risk. There was no continuous linear association between
haemoglobin levels and mortality risk. Both lower and higher
haemoglobin levels were associated with higher mortality risks.
Prior Studies
Previous reports have separately examined the effects of
anaemia or existing CVD on the risk of major outcomes.
Investigations on the effects of anaemia have mostly focused on
people with chronic kidney disease and have largely confirmed the
related high risk of mortality [1,5]. Other reports have consistently
shown excess mortality risk in the presence of a prior CVD,
regardless of diabetes status [10,19,20]. Available studies on
anaemia and mortality risk in nondiabetics with existing CVD
have been inconsistent, with findings ranging from no association
in one study [21] to significant adverse association in two others
[22,23]. There is no similar data for people with diabetes.
We found that in both people with and without diabetes,
anaemia was associated with increased risk of mortality in
Figure 2. Incident all-cause and cardiovascular disease (CVD) mortality (per 1000 person-years of follow-up) in participants with
and without diabetes, with further stratification by status for anaemia and existing CVD. + denotes the presence of the characteristic,
and – denotes its absence.
doi:10.1371/journal.pone.0041875.g002
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participants with prior CVD. In accordance with our results,
previous population-based studies found that the association
between haemoglobin levels and cardiac events, if any, was not
linear [24]. However, splines and polynomial models showed that
excess mortality would occur more in relation with lower than
higher haemoglobin levels.
Mechanisms of Effects
Anaemia in diabetes has been attributed to erythropoietin
(EPO) deficiency subsequent to renal complications [1]. There are
suggestions however that it is more complex and multifactorial and
also include inflammation, nutritional deficiencies, autoimmune
disease, drugs and hormonal changes [25]. The normocytic
normochromic nature of anaemia, and the inverse relationship
between haematocrit and C-reative protein levels in diabetes
support the possible role of inflammation [26]. Haemoglobin
concentrations are inversely related with glycated albumin [26]
and hyperglycaemia is possibly associated with decreased eryth-
rocytes lifespan [27], indicating a likely contribution of glucose
control to anaemia.
Anaemia Correction and Mortality Risk
Trials of anaemia correction to reduce cardiovascular risk
conducted so far, exclusively in people with CKD, support a
harmful effect of anaemia correction particularly when erythro-
poiesis-stimulating agents are used to raise haemoglobin levels into
‘normal range’ [28,29,30]. Whether those adverse outcomes were
the effects of achieved haemoglobin, or strategies for correcting
anaemia, have not been elucidated [31]. In general, available
results should be interpreted with caution, with suggestions
however that, for the time being, aggressive normalisation of
haemoglobin levels in CKD patients with anaemia should be
avoided. Evidence from others field suggests that anaemia
correction using erythropoiesis stimulating agents is also harmful
in patients with cancers [32], but not in those with heart failure
[33]. However, caution is needed when extrapolating findings
from trials in CKD patients to a broader population with may be
less severe anaemia [7].
Limitations and Strengths
Our study has some limitations. We lacked data on kidney
function and could not account for possible effects of nephropathy
[8]. Some studies [8], but not all [7], have found interactions
between anaemia and presence of CKD for mortality risk, and
were modulated by diabetes status and existence of a prior CVD.
The current analyses were based on physician diagnosis.
Therefore some participants with undiagnosed diabetes would
have been misclassified as nondiabetics. Strengths of this study
include the large number of participants, randomly selected from
the general population, and consistency of survey methods across
included cohorts, making our findings generalizable to broader
populations. Unlike most previous studies, we used advanced
Figure 3. Effect of various coding of total haemoglobin on the association with cardiovascular disease (upper panels) and all-cause
(lower panels) mortality in age, sex and cohort adjusted Cox regression models. The solid curve depicts the shape of the shape of the
association across the continuum of total haemoglobin, and the shaded area if for the 95% confidence interval around the curve.
doi:10.1371/journal.pone.0041875.g003
Diabetes Mellitus, Anaemia and Mortality
PLoS ONE | www.plosone.org 6 August 2012 | Volume 7 | Issue 8 | e41875
methods such as restricted cubic splines to carefully examine the
shape of the associations of total haemoglobin with mortality risks.
Indeed, assuming the linearity of the continuous predictor-
outcome association without further investigation, can lead to
incorrect interpretation of the effects of the predictor on the
outcome, particularly when the underlying relationship is not
linear [34]. Systematically testing the significance of simple
predictor transformations (restricted cubic splines for instance)
has been advocated as a mean for exploring non-linearity [34].
Conclusions and Perspectives
In conclusion, anaemia is a determinant of all-cause and
cardiovascular mortality. Diabetic individuals with anaemia but no
prior CVD have risks of mortality similar to those among CVD
survivors with diabetes, but no anaemia. The previous focus on
EPO for anaemia correction still leaves unaddressed other
determinants of chronic anaemia in diabetes. Addressing these
determinants and non-optimal cardiovascular risk profile may
improve the outcomes of patients. To be effective however,
interventions should be implemented early in routine diabetes
care, and not at the kidney impairment stage [2]. Anaemia can
affect the interpretation of values of HbA1c, the standard test for
metabolic control monitoring in diabetes. Systematic screening for
anaemia would help identifying a subgroup of highly vulnerable
diabetic patients whose outcomes may potentially be modified.
Currently, people with diabetes are routinely screened for
cardiovascular disease [35], not for anaemia while both, based
on our findings convey similar mortality risk.
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